Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE Trial: Partial Cystectomy in Muscle-Invasive Bladder Cancer
NCT06290687Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Sep 2026
- Primary completion
- Dec 2026
01
Overview
Phase 2, open-label trial in bladder carcinoma (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Recurrence-Free Survival at 24 months. Planned start Sep 2026; status: withdrawn.
02
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT06290687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290687.